Skip to content

Automated Overnight Closed-loop Glucose Control in Young People With Type 1 Diabetes

Open Randomised, Two Period Cross-over Study to Assess the Feasibility, Efficacy and Safety of Automated Closed-loop Glucose Control Initiated at the Time of Dinner or Before Sleep in Children and Adolescents With Type 1 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00989898
Acronym
APCam05
Enrollment
16
Registered
2009-10-06
Start date
2009-02-28
Completion date
2011-12-31
Last updated
2012-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

T1D, closed-loop systems, overnight hypoglycaemia

Brief summary

Children and adolescents with type 1 diabetes need regular insulin injections or continuous insulin delivery with an insulin pump in order to keep blood sugar levels normal. The investigators know that keeping blood sugars in the normal range can prevent long term diabetes complications involving the eyes, kidneys and heart. However, achieving treatment goals can be very difficult as the tighter the investigators try to control blood glucose levels, the greater the risk for the young person to develop symptoms and signs of low glucose levels (hypoglycaemia). This is a particular problem at night. One solution is to develop a system whereby the amount of insulin injected is very closely matched to the blood sugar levels on a continuous basis. In a closed loop system, for example, a continuous glucose sensor communicates with a computer algorithm which drives an insulin pump. The investigators have been developing such a system in Cambridge over the last year with funding from the Juvenile Diabetes Research Foundation. The investigators have found that this system is very effective at preventing hypoglycaemia in young people with diabetes. Until now the information from the sensor has been entered manually into the computer and the pump settings have also been changed manually. The investigators now need to move onto the next step which is to fully automate the system. The studies will be done in a clinical research facility. The investigators will study the young people on two nights in order to find out if the closed loop system started early in the evening is as effective as when it is started later before sleep. 12 young people will be recruited from diabetes clinics in the East Anglia region. The studies will provide further important information concerning the safety, efficacy and utility of closed loop systems.

Interventions

Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.

Sponsors

Cambridge University Hospitals NHS Foundation Trust
CollaboratorOTHER
University of Cambridge
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Signed informed consent obtained before study-related activities. Study-related activities are any procedure that would not have been performed during standard medical care. * The subject is between 6 and 18 years of age (inclusive). * The subject has type 1 diabetes, as defined by WHO for at least 6 months or confirmed C-peptide negative. * The subject will have been on insulin pump for at least 3 months

Exclusion criteria

* Non-type 1 diabetes mellitus including those secondary to chronic disease * Any other physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results * Taking medication likely to interfere with interpretation of the results * Experienced recurrent severe hypoglycaemic unawareness (as judged by the investigator). * Known or suspected allergy against insulin. * Patients with clinical significant nephropathy, neuropathy or proliferative retinopathy as judged by the investigator.

Design outcomes

Primary

MeasureTime frame
The primary outcome measure is overnight glucose control as measured by plasma glucose concentration between midnight and 8:00 a.m. in the two Time Schedules (closed-loop control starting at 1800 or 2100).midnight to 8:00 am

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026